Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel Free RNA Stock Alerts

Avidity Biosciences (RNA) Financials

Avidity Biosciences logo
$11.68 +0.19 (+1.65%)
As of 03:36 PM Eastern
Compare
Annual Income Statements for Avidity Biosciences

Annual Income Statements for Avidity Biosciences

This table shows Avidity Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -11 -25 -44 -118 -174 -212 -322 -685
Consolidated Net Income / (Loss)		 -11 -25 -44 -118 -174 -212 -322 -685
Net Income / (Loss) Continuing Operations		 -11 -25 -44 -118 -174 -212 -322 -685
Total Pre-Tax Income 		-10 -25 -44 -118 -174 -212 -322 -685
Total Operating Income		 -10 -17 -44 -118 -179 -236 -379 -746
Total Gross Profit		 0.38 2.32 6.79 9.33 9.22 9.56 11 19
Total Revenue		 0.38 2.32 6.79 9.33 9.22 9.56 11 19
Operating Revenue		 0.38 2.32 6.79 9.33 9.22 9.56 11 19
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 11 20 51 127 188 245 390 765
Selling, General & Admin Expense		 2.44 5.11 13 26 38 54 86 206
Research & Development Expense		 8.44 15 38 101 150 191 304 559
Total Other Income / (Expense), net		 0.00 -7.40 -0.08 0.04 4.92 23 57 61
Interest & Investment Income		 0.00 0.00 0.21 0.10 4.98 24 57 63
Other Income / (Expense), net		 0.00 -0.02 -0.08 -0.06 -0.06 -0.59 -0.25 -1.94
Basic Earnings per Share		 ($4.53) ($9.12) ($2.05) ($2.85) ($3.34) ($2.91) ($2.89) ($4.97)
Weighted Average Basic Shares Outstanding		 2.48M 2.71M 21.66M 41.43M 52.16M 73.01M 111.58M 137.71M
Diluted Earnings per Share		 ($4.53) ($9.12) ($2.05) ($2.85) ($3.34) ($2.91) ($2.89) ($4.97)
Weighted Average Diluted Shares Outstanding		 2.48M 2.71M 21.66M 41.43M 52.16M 73.01M 111.58M 137.71M
Weighted Average Basic & Diluted Shares Outstanding		 2.48M 2.71M 21.66M 41.43M 70.81M 79.72M 120.21M 155.15M

Quarterly Income Statements for Avidity Biosciences

This table shows Avidity Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -52 -60 -69 -71 -80 -102 -7.45 -157 -174 -237 -17
Consolidated Net Income / (Loss)		 -52 -60 -69 -71 -80 -102 -7.45 -157 -174 -237 -17
Net Income / (Loss) Continuing Operations		 -52 -60 -69 -71 -80 -102 -7.45 -157 -174 -237 -17
Total Pre-Tax Income 		-52 -60 -69 -71 -80 -102 -7.45 -157 -174 -237 -17
Total Operating Income		 -59 -67 -77 -83 -98 -121 -7.45 -171 -189 -254 -17
Total Gross Profit		 2.82 2.19 3.54 2.05 2.34 2.97 1.57 3.85 12 0.86 20
Total Revenue		 2.82 2.19 3.54 2.05 2.34 2.97 1.57 3.85 12 0.86 20
Operating Revenue		 2.82 2.19 3.54 2.05 2.34 2.97 1.57 3.85 12 0.86 20
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 61 69 81 85 100 124 9.03 175 201 255 37
Selling, General & Admin Expense		 14 16 14 21 23 28 2.09 37 46 89 20
Research & Development Expense		 48 53 67 64 77 96 6.94 138 155 167 17
Total Other Income / (Expense), net		 6.27 6.30 8.33 12 18 19 0.00 14 14 17 0.65
Other Income / (Expense), net		 -0.01 -0.11 -0.10 -0.12 -0.23 0.20 0.00 -0.65 -0.38 -0.48 0.65
Basic Earnings per Share		 ($0.71) ($0.80) ($0.79) ($0.65) ($0.65) ($0.80) ($0.44) ($1.21) ($1.27) ($1.59) ($0.97)
Weighted Average Basic Shares Outstanding		 74.10M 73.01M 87.21M 106.93M 123.38M 111.58M 17.11M 129.62M 137.90M 137.71M 17.11M
Diluted Earnings per Share		 ($0.71) ($0.80) ($0.79) ($0.65) ($0.65) ($0.80) ($0.44) ($1.21) ($1.27) ($1.59) ($0.97)
Weighted Average Diluted Shares Outstanding		 74.10M 73.01M 87.21M 106.93M 123.38M 111.58M 17.11M 129.62M 137.90M 137.71M 17.11M
Weighted Average Basic & Diluted Shares Outstanding		 74.10M 79.72M 95.64M 109.80M 119.31M 120.21M - 128.65M 150.68M 155.15M 17.11M

Annual Cash Flow Statements for Avidity Biosciences

This table details how cash moves in and out of Avidity Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -4.56 91 227 -1.01 20 -155 37 163
Net Cash From Operating Activities		 -9.66 2.49 -37 -95 -136 -119 -301 -650
Net Cash From Continuing Operating Activities		 -9.66 2.49 -37 -95 -136 -119 -301 -650
Net Income / (Loss) Continuing Operations		 -11 -25 -44 -118 -174 -212 -322 -685
Consolidated Net Income / (Loss)		 -11 -25 -44 -118 -174 -212 -322 -685
Depreciation Expense		 0.38 0.35 0.37 0.64 1.39 2.10 2.78 4.15
Amortization Expense		 0.07 0.07 0.01 0.18 -0.62 -11 -21 -13
Non-Cash Adjustments To Reconcile Net Income		 0.43 7.45 4.60 18 30 41 55 102
Changes in Operating Assets and Liabilities, net		 0.65 19 2.26 4.63 7.07 61 -15 -60
Net Cash From Investing Activities		 -0.05 -0.24 -7.79 -83 -190 -130 -854 -38
Net Cash From Continuing Investing Activities		 -0.05 -0.24 -7.79 -83 -190 -130 -854 -38
Purchase of Property, Plant & Equipment		 -0.05 -0.24 -1.09 -3.74 -2.82 -4.23 -7.07 -13
Purchase of Investments		 0.00 0.00 -6.69 -85 -356 -461 -1,434 -1,107
Sale and/or Maturity of Investments		 - 0.00 0.00 6.58 169 335 586 1,086
Other Investing Activities, net		 - - - - - 0.00 0.00 -4.07
Net Cash From Financing Activities		 5.14 89 272 176 346 94 1,192 851
Net Cash From Continuing Financing Activities		 5.14 89 272 176 346 94 1,192 851
Issuance of Common Equity		 0.00 0.00 275 176 346 94 1,192 863
Other Financing Activities, net		 0.16 0.07 - - - 0.00 0.00 -12
Effect of Exchange Rate Changes		 - - - - - 0.00 0.00 0.14

Quarterly Cash Flow Statements for Avidity Biosciences

This table details how cash moves in and out of Avidity Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -68 99 286 107 -206 -150 0.00 -10 106 32 268
Net Cash From Operating Activities		 -37 17 -70 -65 -66 -100 -11 -200 -156 -170 -31
Net Cash From Continuing Operating Activities		 -37 17 -70 -65 -66 -100 -11 -200 -156 -170 -31
Net Income / (Loss) Continuing Operations		 -52 -60 -69 -71 -80 -102 -7.45 -157 -174 -237 -17
Consolidated Net Income / (Loss)		 -52 -60 -69 -71 -80 -102 -7.45 -157 -174 -237 -17
Depreciation Expense		 0.57 0.62 0.64 0.69 0.71 0.74 0.05 0.81 1.06 1.50 0.15
Amortization Expense		 -2.97 -3.24 -2.96 -4.48 -6.85 -7.17 0.06 -3.48 -2.41 -1.49 0.84
Non-Cash Adjustments To Reconcile Net Income		 11 11 11 14 15 15 1.21 18 20 45 12
Changes in Operating Assets and Liabilities, net		 7.41 69 -10 -4.06 6.01 -6.16 -4.97 -58 -0.52 22 -28
Net Cash From Investing Activities		 -31 51 -33 -275 -482 -64 0.00 185 -588 207 -2.10
Net Cash From Continuing Investing Activities		 -31 51 -33 -275 -482 -64 0.00 185 -588 207 -2.10
Purchase of Property, Plant & Equipment		 -0.92 -0.86 -0.92 -0.53 -1.70 -3.92 0.00 -3.34 -0.71 -5.51 -2.10
Net Cash From Financing Activities		 0.04 32 389 447 342 14 11 3.77 850 -5.09 302
Net Cash From Continuing Financing Activities		 0.04 32 389 447 342 14 11 3.77 850 -5.09 302
Issuance of Common Equity		 0.04 32 389 447 342 14 11 3.77 850 7.32 302

Annual Balance Sheets for Avidity Biosciences

This table presents Avidity Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 97 334 428 639 629 1,564 8.35
Total Current Assets		 96 332 411 623 611 1,542 2.85
Cash & Equivalents		 95 321 320 340 185 220 0.00
Prepaid Expenses		 1.10 3.54 5.60 12 16 41 1.54
Other Current Assets		 - - - - - - 1.31
Plant, Property, & Equipment, net		 0.63 1.47 4.81 6.25 8.38 13 2.72
Total Noncurrent Assets		 0.60 0.30 12 9.60 8.87 8.94 2.78
Other Noncurrent Operating Assets		 0.60 0.30 12 9.60 8.87 8.94 2.78
Total Liabilities & Shareholders' Equity		 97 334 428 639 629 1,564 8.35
Total Liabilities		 28 28 46 61 128 139 71
Total Current Liabilities		 10 15 30 52 81 98 42
Accounts Payable		 2.31 7.75 14 33 34 8.46 4.40
Accrued Expenses		 - - - - - 65 12
Current Deferred Revenue		 3.84 3.69 4.86 5.04 28 21 22
Other Current Liabilities		 - - 1.77 3.11 3.64 3.84 3.67
Total Noncurrent Liabilities		 17 13 16 8.82 47 41 29
Noncurrent Deferred Revenue		 15 12 6.53 1.24 41 38 29
Other Noncurrent Operating Liabilities		 0.44 0.94 9.96 7.58 6.21 2.96 0.57
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -65 306 381 578 501 1,425 -63
Total Preferred & Common Equity		 -65 306 381 578 501 1,425 -63
Preferred Stock		 0.00 0.00 - - - - 0.00
Total Common Equity		 -65 306 381 578 501 1,425 -63
Common Stock		 -43 373 566 939 1,071 2,315 0.00
Retained Earnings		 -22 -67 -185 -359 -571 -893 0.00
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.01 -0.19 -2.70 0.13 2.90 0.00
Other Equity Adjustments		 - - - - - - -63

Quarterly Balance Sheets for Avidity Biosciences

This table presents Avidity Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 431 614 611 573 951 1,347 1,641 1,459 1,369 2,134 292
Total Current Assets		 414 597 595 555 934 1,329 1,622 1,435 1,251 1,966 286
Cash & Equivalents		 144 119 154 86 471 576 370 254 244 350 268
Prepaid Expenses		 8.92 11 18 13 19 30 33 55 67 90 2.58
Other Current Assets		 - - - - - - - - - - 15
Plant, Property, & Equipment, net		 6.04 7.85 7.78 8.13 8.66 8.50 9.49 16 21 22 4.34
Total Noncurrent Assets		 9.79 8.98 8.47 9.55 8.35 10 9.41 8.46 98 147 2.46
Other Noncurrent Operating Assets		 9.79 8.98 8.47 9.55 8.35 10 9.41 8.46 98 147 2.46
Total Liabilities & Shareholders' Equity		 431 614 611 573 951 1,347 1,641 1,459 1,369 2,134 292
Total Liabilities		 54 55 52 56 121 126 137 130 176 248 58
Total Current Liabilities		 43 48 45 49 75 84 91 85 135 170 22
Accounts Payable		 26 34 32 32 37 41 50 54 3.91 9.63 0.81
Accrued Expenses		 - - - - - - - - 95 137 9.07
Current Deferred Revenue		 5.45 5.06 3.81 1.97 26 27 20 14 14 19 9.34
Other Current Liabilities		 3.09 3.13 3.15 3.60 3.73 3.77 3.80 3.88 3.93 3.97 2.68
Total Noncurrent Liabilities		 11 6.98 6.36 6.98 46 42 46 45 41 78 36
Capital Lease Obligations		 8.19 - - 6.98 5.42 - - 2.09 - - 0.00
Noncurrent Deferred Revenue		 2.71 0.00 0.00 0.00 40 38 42 43 40 32 36
Other Noncurrent Operating Liabilities		 - 6.98 6.36 - - 4.62 3.80 - 1.21 46 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 377 559 559 517 831 1,221 1,503 1,329 1,193 1,886 234
Total Preferred & Common Equity		 377 559 559 517 831 1,221 1,503 1,329 1,193 1,886 234
Preferred Stock		 - - - - - - - - - - 0.00
Total Common Equity		 377 559 559 517 831 1,221 1,503 1,329 1,193 1,886 234
Common Stock		 689 971 1,020 1,030 1,471 1,932 2,287 2,335 2,357 3,225 222
Retained Earnings		 -308 -411 -458 -510 -640 -710 -791 -1,009 -1,166 -1,341 12
Accumulated Other Comprehensive Income / (Loss)		 -3.46 -1.53 -2.67 -1.88 -0.46 -0.45 7.10 2.77 1.78 1.77 0.00
Other Equity Adjustments		 - - - - - - - - - - 0.00

Annual Metrics And Ratios for Avidity Biosciences

This table displays calculated financial ratios and metrics derived from Avidity Biosciences' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 511.87% 192.67% 37.41% -1.09% 3.64% 13.99% 72.11%
EBITDA Growth		 0.00% -68.57% -159.75% -166.76% -51.92% -37.69% -62.15% -90.08%
EBIT Growth		 0.00% -65.24% -155.68% -166.31% -51.52% -31.97% -60.54% -97.24%
NOPAT Growth		 0.00% -65.10% -155.46% -166.62% -51.56% -31.68% -60.84% -96.85%
Net Income Growth		 0.00% -120.52% -79.33% -166.06% -47.44% -21.97% -51.87% -112.42%
EPS Growth		 0.00% -101.32% 77.52% -39.02% -17.19% 12.87% 0.69% -71.97%
Operating Cash Flow Growth		 0.00% 125.79% -1,590.64% -155.44% -43.72% 12.63% -152.70% -116.19%
Free Cash Flow Firm Growth		 0.00% 0.00% -443.06% -176.16% -44.26% 11.75% -175.10% -108.41%
Invested Capital Growth		 0.00% 0.00% -8.23% -7.78% -35.41% -189.68% 19.08% 89.20%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -3.02% 11.04% -5.68% 7.71% -10.13%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -23.18% -9.43% -6.89% -16.98% -20.32%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -23.25% -8.91% -6.11% -16.58% -21.86%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -23.23% -8.94% -6.09% -16.71% -21.80%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -23.25% -7.36% -4.93% -14.91% -24.53%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -630.77% -1.83% 3.00% 0.00% -18.90%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -27.71% -16.09% -10.52% 31.87% -63.07% -12.04%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -3.75% 34.80% -76.84% -12.60%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -32.84% -58.26% -421.54% 10.18% -179.29%
Profitability Metrics		 - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -2,649.60% -729.97% -647.86% -1,257.72% -1,931.90% -2,566.58% -3,651.05% -4,032.31%
Operating Margin		 -2,769.92% -747.39% -652.38% -1,265.83% -1,939.65% -2,464.41% -3,477.43% -3,977.30%
EBIT Margin		 -2,769.92% -748.04% -653.48% -1,266.49% -1,940.26% -2,470.63% -3,479.71% -3,987.66%
Profit (Net Income) Margin		 -2,959.37% -1,066.58% -653.53% -1,265.38% -1,886.33% -2,219.87% -2,957.71% -3,650.39%
Tax Burden Percent		 106.84% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 142.58% 100.01% 99.91% 97.22% 89.85% 85.00% 91.54%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -35.66% -23.62% -34.32% -36.27% -39.34% -33.47% -43.98%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -17.90% -20.59% -31.02% -33.57% -37.27% -34.59% -42.47%
Return on Assets (ROA)		 0.00% -25.52% -20.59% -30.99% -32.63% -33.49% -29.40% -38.88%
Return on Common Equity (ROCE)		 0.00% 33.60% -15.15% -34.32% -36.27% -39.34% -33.47% -43.98%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 37.84% -14.48% -30.94% -30.10% -42.38% -22.62% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.35 -12 -31 -83 -125 -165 -265 -522
NOPAT Margin		 -1,938.94% -523.17% -456.67% -886.08% -1,357.75% -1,725.09% -2,434.20% -2,784.11%
Net Nonoperating Expense Percent (NNEP)		 0.00% -27.99% -6.38% -9.64% -9.60% -7.84% -5.44% -10.16%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -21.66% -32.93% -18.61% -30.92%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 644.06% 220.44% 198.35% 280.88% 409.07% 566.84% 791.41% 1,095.92%
R&D to Revenue		 2,225.86% 626.95% 554.03% 1,084.95% 1,630.57% 1,997.57% 2,786.02% 2,981.39%
Operating Expenses to Revenue		 2,869.92% 847.39% 752.38% 1,365.83% 2,039.65% 2,564.41% 3,577.43% 4,077.30%
Earnings before Interest and Taxes (EBIT)		 -10 -17 -44 -118 -179 -236 -379 -748
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -10 -17 -44 -117 -178 -245 -398 -756
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 3.13 2.92 2.09 1.34 2.43 6.44
Price to Tangible Book Value (P/TBV)		 0.00 0.00 3.13 2.92 2.09 1.34 2.43 6.44
Price to Revenue (P/Rev)		 395.78 64.68 141.11 119.53 131.02 70.15 318.39 579.49
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 83.95 92.76 76.05 64.81 7.87 180.60 489.01
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 78.19 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 22.80 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.07 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.30 -1.11 -1.07 -1.06 -1.12 -1.09 -1.03
Leverage Ratio		 0.00 1.40 1.15 1.11 1.11 1.17 1.14 1.13
Compound Leverage Factor		 0.00 1.99 1.15 1.11 1.08 1.06 0.97 1.04
Debt to Total Capital		 0.00% 6.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 3.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 2.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 182.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -88.43% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.27 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 5.32 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.10 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.37 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 7.42 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.15 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 3.44 21.21 14.07 11.32 1.67 14.50 22.80
Noncontrolling Interest Sharing Ratio		 0.00% 194.22% 35.87% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.00 9.35 22.74 13.86 12.00 7.58 15.73 9.20
Quick Ratio		 0.00 9.24 22.50 13.67 11.77 7.38 15.32 8.68
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 8.54 -29 -81 -117 -103 -283 -590
Operating Cash Flow to CapEx		 -19,704.08% 1,059.57% -3,398.99% -2,535.11% -4,827.06% -2,816.08% -4,258.00% -4,883.56%
Free Cash Flow to Firm to Interest Expense		 0.00 1.16 -140.16 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.34 -177.59 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.31 -182.82 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.02 0.03 0.02 0.02 0.02 0.01 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 3.68 6.47 2.97 1.67 1.31 1.04 1.04
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 -21 -22 -24 -33 -95 -77 -8.27
Invested Capital Turnover		 0.00 -0.22 -0.32 -0.40 -0.33 -0.15 -0.13 -0.44
Increase / (Decrease) in Invested Capital		 0.00 -21 -1.70 -1.74 -8.54 -62 18 68
Enterprise Value (EV)		 0.00 195 630 709 598 75 1,968 9,171
Market Capitalization		 150 150 958 1,115 1,209 671 3,470 10,868
Book Value per Share		 $0.00 ($24.09) $8.16 $8.13 $10.61 $6.76 $11.94 $11.21
Tangible Book Value per Share		 $0.00 ($24.09) $8.16 $8.13 $10.61 $6.76 $11.94 $11.21
Total Capital		 0.00 74 306 381 578 501 1,425 1,689
Total Debt		 0.00 4.54 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 1.77 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -90 -328 -406 -611 -595 -1,501 -1,697
Capital Expenditures (CapEx)		 0.05 0.24 1.09 3.74 2.82 4.23 7.07 13
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -6.36 -11 -24 -40 -65 -57 -94
Debt-free Net Working Capital (DFNWC)		 0.00 88 317 381 571 531 1,444 1,603
Net Working Capital (NWC)		 0.00 85 317 381 571 531 1,444 1,603
Net Nonoperating Expense (NNE)		 3.87 13 13 35 49 47 57 162
Net Nonoperating Obligations (NNO)		 0.00 -90 -329 -406 -611 -595 -1,501 -1,697
Total Depreciation and Amortization (D&A)		 0.46 0.42 0.38 0.82 0.77 -9.17 -19 -8.37
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -274.43% -162.81% -257.99% -430.32% -677.03% -525.14% -500.39%
Debt-free Net Working Capital to Revenue		 0.00% 3,803.97% 4,672.03% 4,090.53% 6,190.74% 5,550.49% 13,253.85% 8,547.17%
Net Working Capital to Revenue		 0.00% 3,684.35% 4,672.03% 4,090.53% 6,190.74% 5,550.49% 13,253.85% 8,547.17%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.05) ($2.85) ($3.34) ($2.91) ($2.89) ($4.97)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 37.58M 47.75M 52.16M 73.01M 111.58M 137.71M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.05) ($2.85) ($3.34) ($2.91) ($2.89) ($4.97)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 37.58M 47.75M 52.16M 73.01M 111.58M 137.71M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($2.05) ($2.85) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 21.66M 41.43M 70.81M 79.72M 120.21M 155.15M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.35 -12 -31 -83 -125 -165 -265 -522
Normalized NOPAT Margin		 -1,938.94% -523.17% -456.67% -886.08% -1,357.75% -1,725.09% -2,434.20% -2,784.11%
Pre Tax Income Margin		 -2,769.92% -1,066.58% -653.53% -1,265.38% -1,886.33% -2,219.87% -2,957.71% -3,650.39%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 -2.35 -212.21 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -1.64 -148.30 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -2.38 -217.44 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -1.67 -153.52 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% -0.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Avidity Biosciences

This table displays calculated financial ratios and metrics derived from Avidity Biosciences' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 0.00 - - - 0.00
DEI Adjusted Shares Outstanding		 - - - - - - 0.00 - - - 0.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - 0.00 - - - 0.00
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 13.54% -20.80% 58.67% -11.70% -17.10% 35.57% 0.00% 88.12% 434.03% -71.07% 1,148.25%
EBITDA Growth		 -36.83% -29.46% -33.23% -57.02% -71.21% -83.12% 0.00% -101.61% -82.33% -100.40% -113.09%
EBIT Growth		 -30.48% -25.55% -33.46% -56.72% -67.75% -80.69% 0.00% -107.62% -92.33% -111.08% -123.29%
NOPAT Growth		 -30.48% -25.40% -34.01% -56.98% -67.39% -81.28% 0.00% -107.13% -92.40% -110.33% -131.88%
Net Income Growth		 -20.09% -19.76% -31.42% -50.54% -53.55% -69.18% 0.00% -122.22% -116.97% -131.87% -123.29%
EPS Growth		 13.41% 10.11% -6.76% 1.52% 8.45% 0.00% 0.00% -86.15% -95.38% -98.75% -120.45%
Operating Cash Flow Growth		 -15.12% 142.11% -43.73% -30.51% -78.35% -705.24% 0.00% -207.16% -138.01% -69.99% -180.49%
Free Cash Flow Firm Growth		 -50.27% 152.98% 94.57% 108.16% 96.29% -775.27% 0.00% -7,382.89% -13,989.94% -139.83% 0.00%
Invested Capital Growth		 12.10% -189.68% -190.50% -350.27% -369.86% 19.08% 0.00% 112.20% 112.24% 89.20% 0.00%
Revenue Q/Q Growth		 21.68% -22.18% 61.56% -42.28% 14.23% 27.27% 0.00% 144.56% 224.28% -93.11% 0.00%
EBITDA Q/Q Growth		 -10.76% -13.81% -14.59% -8.70% -20.77% -21.74% 0.00% -27.97% -9.22% -33.81% 0.00%
EBIT Q/Q Growth		 -11.07% -14.00% -15.62% -7.06% -18.88% -22.79% 0.00% -30.19% -10.12% -34.76% 0.00%
NOPAT Q/Q Growth		 -11.38% -13.85% -15.65% -7.05% -18.77% -23.29% 0.00% -30.13% -10.32% -34.78% 0.00%
Net Income Q/Q Growth		 -11.34% -15.44% -13.92% -2.81% -13.57% -27.19% 0.00% -35.88% -10.89% -35.92% 0.00%
EPS Q/Q Growth		 -7.58% -12.68% 1.25% 17.72% 0.00% -23.08% 0.00% -34.44% -4.96% -25.20% 0.00%
Operating Cash Flow Q/Q Growth		 26.13% 144.85% -526.52% 7.64% -0.94% -52.21% 0.00% -59.95% 21.78% -8.71% 0.00%
Free Cash Flow Firm Q/Q Growth		 -24.80% 134.95% -112.24% 252.82% -156.79% -6,254.61% 0.00% -69.18% -9.88% -8.16% 0.00%
Invested Capital Q/Q Growth		 -4.68% -421.54% 15.89% 1.94% -9.23% 10.18% 0.00% 119.40% 9.55% -179.29% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -2,166.00% -3,167.81% -2,246.88% -4,231.30% -4,473.54% -4,279.04% -466.62% -4,534.81% -1,527.33% -29,644.88% -79.66%
Operating Margin		 -2,080.38% -3,043.46% -2,178.58% -4,040.39% -4,200.94% -4,069.59% -473.74% -4,448.71% -1,513.47% -29,590.47% -88.01%
EBIT Margin		 -2,080.84% -3,048.24% -2,181.43% -4,046.06% -4,210.87% -4,062.83% -473.55% -4,465.64% -1,516.52% -29,645.93% -84.71%
Profit (Net Income) Margin		 -1,857.98% -2,756.18% -1,943.41% -3,461.76% -3,441.70% -3,439.49% -473.55% -4,089.29% -1,398.33% -27,569.88% -84.71%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 89.29% 90.42% 89.09% 85.56% 81.73% 84.66% 100.00% 91.57% 92.21% 93.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -45.22% -39.34% -32.91% -28.36% -27.76% -33.47% 0.00% -37.76% -32.44% -43.98% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,756.07% -5,027.90% 0.00% 0.00%
Operating Return on Assets (OROA)		 -42.03% -45.99% -30.29% -43.80% -38.48% -40.39% 0.00% -35.28% -16.77% -315.74% 0.00%
Return on Assets (ROA)		 -37.53% -41.58% -26.99% -37.47% -31.46% -34.19% 0.00% -32.30% -15.46% -293.63% 0.00%
Return on Common Equity (ROCE)		 -45.22% -39.34% -32.91% -28.36% -27.76% -33.47% 0.00% -37.76% -32.44% -43.98% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -39.08% 0.00% -27.52% -20.68% -18.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -41 -47 -54 -58 -69 -85 -5.22 -120 -132 -178 -12
NOPAT Margin		 -1,456.26% -2,130.42% -1,525.00% -2,828.27% -2,940.66% -2,848.72% -331.62% -3,114.10% -1,059.43% -20,713.33% -61.60%
Net Nonoperating Expense Percent (NNEP)		 -2.43% -2.28% -1.98% -1.38% -1.10% -1.68% 0.00% -3.02% -2.44% -3.69% -3.39%
Return On Investment Capital (ROIC_SIMPLE)		 - -9.33% - - - -5.94% - -10.04% -7.01% -10.55% -5.17%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 487.19% 735.02% 392.27% 1,013.74% 996.28% 953.18% 132.74% 958.25% 371.41% 10,318.84% 103.17%
R&D to Revenue		 1,693.19% 2,408.44% 1,886.31% 3,126.65% 3,304.67% 3,216.41% 441.00% 3,590.46% 1,242.07% 19,371.63% 84.83%
Operating Expenses to Revenue		 2,180.38% 3,143.46% 2,278.58% 4,140.39% 4,300.94% 4,169.59% 573.74% 4,548.71% 1,613.47% 29,690.47% 188.01%
Earnings before Interest and Taxes (EBIT)		 -59 -67 -77 -83 -98 -121 -7.45 -172 -189 -255 -17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -61 -69 -80 -87 -105 -127 -7.34 -174 -191 -255 -16
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.91 1.34 2.28 3.20 3.35 2.43 0.00 2.87 2.97 6.44 0.98
Price to Tangible Book Value (P/TBV)		 0.91 1.34 2.28 3.20 3.35 2.43 0.00 2.87 2.97 6.44 0.98
Price to Revenue (P/Rev)		 46.64 70.15 173.97 368.60 498.49 318.39 0.00 319.07 268.61 579.49 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 235.31 357.62 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 7.87 90.21 246.03 341.46 180.60 0.00 208.79 178.72 489.01 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.12 -1.08 -1.05 -1.05 -1.09 0.00 -1.03 -1.02 -1.03 -1.14
Leverage Ratio		 1.12 1.17 1.13 1.10 1.10 1.14 0.00 1.13 1.11 1.13 1.25
Compound Leverage Factor		 1.00 1.06 1.00 0.94 0.90 0.96 0.00 1.03 1.03 1.05 1.25
Debt to Total Capital		 1.33% 0.00% 0.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 1.33% 0.00% 0.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 98.67% 100.00% 99.35% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.03 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 2.33 0.00 3.43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.03 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.04 0.00 -0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 3.45 0.00 5.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.04 0.00 -0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 4.59 2.55 9.30 18.72 22.28 15.04 0.00 11.03 13.41 23.64 3.31
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 11.40 7.58 12.47 15.78 17.76 15.73 0.00 9.26 11.57 9.20 13.04
Quick Ratio		 11.14 7.38 12.22 15.43 17.39 15.32 0.00 8.76 11.04 8.68 12.23
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -44 15 -1.86 2.85 -1.62 -103 0.00 -207 -228 -246 22
Operating Cash Flow to CapEx		 -3,986.02% 1,912.05% -7,691.80% -12,241.81% -3,850.65% -2,550.33% 0.00% -5,972.66% -21,934.41% -3,080.62% -1,484.41%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.02 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.43 1.31 1.32 1.30 1.15 1.04 0.00 0.74 1.35 1.04 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -18 -95 -80 -78 -85 -77 0.00 9.52 10 -8.27 -34
Invested Capital Turnover		 -0.52 -0.15 -0.20 -0.22 -0.20 -0.13 0.00 -0.31 -0.56 -0.44 0.00
Increase / (Decrease) in Invested Capital		 2.50 -62 -52 -61 -67 18 0.00 88 96 68 -34
Enterprise Value (EV)		 -63 75 981 2,608 3,455 1,968 0.00 2,240 3,730 9,171 -39
Market Capitalization		 473 671 1,891 3,907 5,043 3,470 0.00 3,423 5,605 10,868 229
Book Value per Share		 $6.98 $6.76 $9.53 $12.77 $13.69 $11.94 $0.00 $9.89 $14.66 $11.21 $13.69
Tangible Book Value per Share		 $6.98 $6.76 $9.53 $12.77 $13.69 $11.94 $0.00 $9.89 $14.66 $11.21 $13.69
Total Capital		 524 501 836 1,221 1,503 1,425 0.00 1,193 1,886 1,689 234
Total Debt		 6.98 0.00 5.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 6.98 0.00 5.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -536 -595 -910 -1,299 -1,589 -1,501 0.00 -1,183 -1,876 -1,697 -268
Capital Expenditures (CapEx)		 0.92 0.86 0.92 0.53 1.70 3.92 0.00 3.34 0.71 5.51 2.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -36 -65 -56 -54 -58 -57 0.00 -68 -80 -94 -4.19
Debt-free Net Working Capital (DFNWC)		 507 531 860 1,245 1,531 1,444 0.00 1,115 1,796 1,603 264
Net Working Capital (NWC)		 507 531 860 1,245 1,531 1,444 0.00 1,115 1,796 1,603 264
Net Nonoperating Expense (NNE)		 11 14 15 13 12 18 2.23 38 42 59 4.54
Net Nonoperating Obligations (NNO)		 -536 -595 -910 -1,299 -1,589 -1,501 0.00 -1,183 -1,876 -1,697 -268
Total Depreciation and Amortization (D&A)		 -2.40 -2.62 -2.32 -3.79 -6.14 -6.43 0.11 -2.66 -1.35 0.01 0.99
Debt-free, Cash-free Net Working Capital to Revenue		 -353.31% -677.03% -518.44% -513.79% -573.89% -525.14% 0.00% -630.49% -381.91% -500.39% 0.00%
Debt-free Net Working Capital to Revenue		 4,999.71% 5,550.49% 7,907.26% 11,742.51% 15,128.33% 13,253.85% 0.00% 10,397.05% 8,607.14% 8,547.17% 0.00%
Net Working Capital to Revenue		 4,999.71% 5,550.49% 7,907.26% 11,742.51% 15,128.33% 13,253.85% 0.00% 10,397.05% 8,607.14% 8,547.17% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.71) ($0.80) ($0.79) ($0.65) ($0.65) ($0.80) $0.00 ($1.21) ($1.27) ($1.59) ($0.97)
Adjusted Weighted Average Basic Shares Outstanding		 74.10M 73.01M 87.21M 106.93M 123.38M 111.58M 0.00 129.62M 137.90M 137.71M 17.11M
Adjusted Diluted Earnings per Share		 ($0.71) ($0.80) ($0.79) ($0.65) ($0.65) ($0.80) $0.00 ($1.21) ($1.27) ($1.59) ($0.97)
Adjusted Weighted Average Diluted Shares Outstanding		 74.10M 73.01M 87.21M 106.93M 123.38M 111.58M 0.00 129.62M 137.90M 137.71M 17.11M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 74.10M 79.72M 95.64M 109.80M 119.31M 120.21M 0.00 128.65M 150.68M 155.15M 17.11M
Normalized Net Operating Profit after Tax (NOPAT)		 -41 -47 -54 -58 -69 -85 -5.22 -120 -132 -178 -12
Normalized NOPAT Margin		 -1,456.26% -2,130.42% -1,525.00% -2,828.27% -2,940.66% -2,848.72% -331.62% -3,114.10% -1,059.43% -20,713.33% -61.60%
Pre Tax Income Margin		 -1,857.98% -2,756.18% -1,943.41% -3,461.76% -3,441.70% -3,439.49% -473.55% -4,089.29% -1,398.33% -27,569.88% -84.71%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Avidity Biosciences’ latest results show a company with strong liquidity, rapidly growing collaboration revenue, and heavy R&D investment, but it is still deeply unprofitable and burning cash at a significant rate. Over the last several years, the main story has been improving access to capital and a larger balance sheet, alongside rising operating expenses as the company pushes its pipeline forward.

  • Cash and investments remain substantial. As of Q3 2025, Avidity reported about $1.88 billion in equity and held $350.2 million in cash plus $1.53 billion in short-term investments, giving it a large liquidity cushion.
  • The balance sheet has strengthened dramatically over the past year. Total assets rose to $2.13 billion in Q3 2025 from $1.64 billion in Q3 2024 and $951.5 million in Q1 2024, largely due to equity issuance and investment buildup.
  • Revenue is trending higher quarter by quarter in 2025. Operating revenue increased from $1.6 million in Q1 2025 to $3.8 million in Q2 and $12.5 million in Q3, before reaching $860,000 in the latest Q4 2025 quarter shown here.
  • Interest and investment income provides meaningful support. In Q4 2025, interest and investment income was $17.9 million, helping offset some of the operating losses.
  • Investing activity has been a source of cash when needed. Q4 2025 showed $207.2 million in net cash from investing activities, driven by sales/maturities of investments exceeding purchases.
  • The company remains able to access capital markets. Avidity issued $7.3 million of common equity in Q4 2025 and much larger amounts in prior quarters, including $850.4 million in Q3 2025.
  • Operating revenue has improved versus the prior-year run rate. Quarterly revenue in 2025 is well above the low-single-million levels seen throughout 2023 and 2024, suggesting better commercial or collaboration traction.
  • R&D spending remains very high. This is expected for a biotech company, but it also means the business is still in investment mode rather than harvest mode.
  • Share count has increased materially over time. Weighted average shares outstanding rose from roughly 70.4 million in Q1 2023 to 137.7 million in Q4 2025, which dilutes existing shareholders.
  • Deferred revenue and accrued liabilities are meaningful. These are not necessarily bad, but they indicate the company has a mix of future obligations and contract-related balances to manage.
  • Losses remain very large. Q4 2025 net loss was $237.1 million, after a $174.4 million loss in Q3 2025 and $157.3 million loss in Q2 2025.
  • Operating expenses continue to dwarf revenue. Q4 2025 operating expenses were $255.3 million versus just $860,000 of revenue, leading to a $254.5 million operating loss.
  • Cash from operations is still negative. Q4 2025 operating cash flow was negative $169.8 million, and the company has consistently posted negative operating cash flow over the period shown.
  • Cash burn has been persistent for years. Even after investing and financing inflows, Avidity has repeatedly posted quarterly net losses and negative operating cash flow, indicating it is still far from self-funding.
  • Recent quarters show a heavier dependence on investment sales and financing. That helps liquidity now, but it also underscores that the company is not yet generating enough from operations to fund itself.

Bottom line: Avidity Biosciences looks financially well-capitalized for a development-stage biotech company, with a sizable cash/investment position and improving revenue trend. However, the core financial challenge remains unchanged: losses and cash burn are still very large, so investors are still underwriting future pipeline execution rather than current profitability.

07/27/26 03:58 PM ETAI Generated. May Contain Errors.

Avidity Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Avidity Biosciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Avidity Biosciences' net income appears to be on an upward trend, with a most recent value of -$684.63 million in 2025, rising from -$11.22 million in 2018. The previous period was -$322.30 million in 2024. Check out Avidity Biosciences' forecast to explore projected trends and price targets.

Avidity Biosciences' total operating income in 2025 was -$745.94 million, based on the following breakdown:
  • Total Gross Profit: $18.76 million
  • Total Operating Expenses: $764.70 million

Over the last 7 years, Avidity Biosciences' total revenue changed from $379 thousand in 2018 to $18.76 million in 2025, a change of 4,848.5%.

Avidity Biosciences' total liabilities were at $71.07 million at the end of 2025, a 48.8% decrease from 2024, and a 158.0% increase since 2019.

In the past 6 years, Avidity Biosciences' cash and equivalents has ranged from $0.00 in 2025 to $340.40 million in 2022, and is currently $0.00 as of their latest financial filing in 2025.

Over the last 7 years, Avidity Biosciences' book value per share changed from 0.00 in 2018 to 11.21 in 2025, a change of 1,120.7%.


Related Companies

Financial statements for NASDAQ:RNA last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel